Infected Wounds

WoundSource Editors's picture

By the WoundSource Editors

Toronto, Canada – November 4, 2019 – MolecuLight Inc., the world's leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, has been informed by the American Medical Association (AMA) that in its summary of panel actions September 2019 meeting, the CPT® Editorial Panel accepted the addition of new Category III codes 0X30T, 0X31T to report "wound bacterial localization and treatment" effective date July 1, 2020 to enable a reimbursement pathway for point-of-care fluorescence wound imaging. At that time a novel code excluding the "X" will be reported by the AMA when the final datafiles are distributed by the AMA. Point-of-care fluorescence wound imaging is achieved using MolecuLight's handheld fluorescence imaging device, the i:X®.

Blog Category: 
WoundSource Practice Accelerator's picture
Preventing Surgical Site Infections

By the WoundSource Editors

The Centers for Disease Control and Prevention (CDC) define a surgical site infection (SSI) as "an infection that occurs after surgery in the part of the body where the surgery took place." The CDC go on to say the infection can be superficial involving just the skin or more serious infections can occur that involve deeper structures, such as tissue under the skin, organs, or implanted devices or materials. The CDC offer tools and guidelines to prevent SSIs and provide education to the public. Public education includes tips and advice on how to prevent patient surgical sites from becoming infected. Although such steps may not always prevent a surgical wound from becoming infected, it is always important to involve the patient in postoperative care.

WoundSource Practice Accelerator's picture
Surgical Wound Infection Assessment

By the WoundSource Editors

With an associated cost of $3.5 billion to $10 billion spent annually on surgical site infections (SSIs) and complications in the United States, it is important to know how to assess for surgical wound complications. There is a difference between the normal cascade response and a brewing infection. Symptoms of infection are often the first clue that there is more occurring in the wound than meets the eye.

WoundSource Practice Accelerator's picture

By the WoundSource Editors

Caseous necrosis: Caseous necrosis is found in tuberculosis, syphilis, and some fungal diseases. It forms in response to intracellular pathogens, such as mycobacteria, and can also be found in association with granulomas. With this type of cell death, the tissue assumes a cheese-like appearance.

Clostridium difficile: Also referred to C. diff, this bacterium can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. On a lesion, semihard nodules may be found, in which case lymph node tuberculosis may be present.

Complex wounds: Wounds that have one or more complicating factor, such as exudate, infection, comorbidity, or polypharmacy. They can be acute or chronic wounds that defy cure with conventional therapies. Treating complex wounds generally requires a multidisciplinary approach.

WoundSource Practice Accelerator's picture
Biofilm

By the WoundSource Editors

Biofilm: this term is frequently used in the wound care space, but biofilm continues to be largely undertreated in wound care. What do the bedside nurse or clinician need to know about biofilm? Should clinicians care less about biofilm on a maintenance or palliative wound versus a wound they are actively trying to heal? Let's address these questions and get to the root of the biofilm in managing complex wound cases.

WoundSource Practice Accelerator's picture
Complex Wounds

By the WoundSource Editors

Complex wounds pose a significant challenge for many health care providers. These wounds are often multifaceted, making treatment tremendously difficult. They represent a substantial burden on the health care industry, with annual costs in North America alone estimated at $10 billion annually. They often also result in patient discomfort and pain, caregiver frustration, individual economic losses, and diminished quality of life.

WoundSource Practice Accelerator's picture
Compression

By the WoundSource Editors

Lymphedema is edema—swelling of tissues caused by fluid in the intracellular space—that is caused by dysfunction or disruption of the lymphatic system. The lymphatic system uses lymphatic vessels to absorb, transfer, and filter fluids from peripheral intracellular spaces and return these fluids to general circulation. When there is an obstruction or a structural change to the lymphatic system, typically experienced in response to surgical or neoplastic changes, the transfer of extracellular fluids from the periphery is inhibited, resulting in localized edema distal to the site of the structural deficiency.

Emily Greenstein's picture
Keywords: 
Morgellons Disease

By Emily Greenstein, APRN, CNP, CWON

I recently presented this topic as a Journal Club presentation for the Association for the Advancement of Wound Care Members. I feel like this is a very important and interesting subject, so I wanted to share it with more people. Morgellons disease (MD) is a disorder that can be considered controversial. One view of it is that the disorder is purely a psychological condition, and the other view is that the disorder is actually a byproduct of another infectious process. My goal is to give you some facts from both sides and allow you to make your own decision.

Gregory Schultz's picture
Biofilm Frequently Asked Questions

By Gregory Schultz, PhD

In my recent WoundSource webinar on the assessment and treatment of chronic wounds and biofilms, I discussed the pathogenesis of chronic wounds and offered a biofilm-based wound care protocol to promote healing.

WoundSource Practice Accelerator's picture
wound biofilm virulence

By the WoundSource Editors

Wound biofilms not only impede healing but also increase the risk of infection. It is essential that wound biofilms be addressed and treated in a prompt, consistent manner. Biofilms have been an ongoing challenge because of the majority of resistant bacteria. Research in antibiofilm technology continues to grow, and it is essential to keep up on the most recent evidenced-based practice literature for improving patients’ outcomes.